

A key focus for managing the COVID-19 pandemic during the flu season is diagnostic testing that can differentiate SARS-CoV-2 from other respiratory infections that have similar symptoms. Several immunoassays and molecular multiplex tests for SARS-CoV-2, Flu A, Flu B and RSV have been EUA approved by the FDA or received a CE mark. Rapid point-of-care lateral flow assays pose a significant benefit for clinicians as it allows them to differentially diagnose a patient with respiratory symptoms using a single swab, all within one appointment.

A successful multiplex assay must demonstrate high specificity for each disease with no cross-reactivity. In addition, the sensitivity of the assay needs to meet the same limit of detection as a singleplex assay in order to be effective. This requires using monoclonal antibodies that have high affinity and specificity for their target molecule.

High Sensitivity MAb Pairs

Meridian Life Science has several high performing pairs for SARS-CoV-2, RSV, Flu A and Flu B which are ideal for use in a multiplex point-of-care assay.

MAbs to SARS-CoV-2 Nucleocapsid

Capture #9547	Detection #9548
*Pair detects Omicron down to 1.3	31 x 10 ² PFU/mL, and 1.88 x 10 ² PFU/mL
for other variants.	

MAb to Flu B Nucleoprotein

Capture #C01746M	Detection #C01747M
Capture #C01747M	Detection #C01744M
Capture #C01744M	Detection #C01897M

MAb to RSV Fusion Protein

Capture #C01769M	Detection #C01773M
Capture #C65063M	Detection #C65065M

MAb to Flu A Nucleoprotein

Capture #C01736M	Detection #C01731M
Capture #C01732M	Detection #C01731M

Ordering information:

IISA

5171 Wilfong Road Memphis, Tennessee 38134 Phone: +1 901-382-8716 Fax: +1 901-333-8223

Email: info@meridianlifescience.com
Orders: orders@meridianlifescience.com
www.MeridianLifeScience.com





